Hemispherx Biopharma exploring possible research programs in Zika virus

Shares of USA-based Hemispherx Biopharma (NYSE: HEB) rose 5.9% to $0.1133 today, after it said it is beginning to consider study designs for potential tests of the activity and potential uses of its natural alpha interferon (Alferon N and Alferon LDO) and rintatolimod (Ampligen) drug formulations against the Zika virus.

The recent orphan drug designations of Ampligen for Ebola and Alferon N for MERS viruses by the European Regulatory authorities demonstrates the global need for drugs that possess broad antiviral activities against emerging viruses.

Zika virus is a member of the flavivirus family. Like West Nile Virus, both viruses are transmitted by bites of the Aedes aegyptic mosquito.  The Zika virus is suspected of causing an increase in babies born in Brazil with abnormally small heads, a serious birth defect known as microcephaly.  At present, there are no known vaccines for Zika.  The World Health Organization estimates there could be 3 million to 4 million cases of Zika in the Americas this year.  Recently, cases of Zika infection have also been reported secondary to sexual contact and blood transfusions.